Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its ⁹⁹ᵐTc tetrofosmin, a SPECT myocardial perfusion imaging agent.
This radiopharmaceutical drug, which is utilized for myocardial perfusion imaging in the US, Europe, and Japan, was originally discovered by GE Healthcare. Dongcheng Pharmaceutical has obtained the license to manufacture and distribute this drug in mainland China. The product is indicated for use in adults with or suspected of having coronary artery disease. It is used for myocardial perfusion imaging under drug loading and resting conditions, requiring two injections to assess changes in myocardial blood flow perfusion.- Flcube.com
